Journal: Frontiers in Cellular Neuroscience

Article Title: Mast Cells Mediate Inflammatory Injury and Aggravate Neurological Impairment in Experimental Subarachnoid Hemorrhage Through Microglial PAR-2 Pathway

doi: 10.3389/fncel.2021.710481

Figure Lengend Snippet: Effect of cromolyn and compound 48/80 on MCs infiltration and degranulation at 24 h after SAH. (A) Toluidine blue staining of mast cells in cortex region (yellow arrow: infiltrated MCs). (B,C) Quantitative analyses of MCs infiltration and degranulation. n = 6. Data are represented as mean ± SD. * P < 0.05 versus sham group. # P < 0.05 versus SAH + vehicle group.

Article Snippet: Mast cell stabilizer cromolyn (purchased from Med-ChemExpress, NJ, United States), MCs degranulator compound 48/80 (purchased from Cayman Chemicals, MI, United States), and PAR2 antagonist ENMD-1068 (purchased from Med-ChemExpress, NJ, United States) were dissolved in saline with a final concentration of 100 mg/kg, 0.5 mg/mL, and 0.5 mg/kg, separately.

Techniques: Staining

Journal: Journal of Medical Case Reports

Article Title: Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report

doi: 10.1186/1752-1947-4-193

Figure Lengend Snippet: Mean symptom scores . Mean symptom scores recorded before the introduction of inhaled sodium cromoglicate and for the first eight weeks after introduction. Symptoms (22 in total) are grouped according to organ systems. Symptoms are recorded daily by patient using a 0-4 scale. Columns are mean scores for two weeks. Error bars are standard error of means. Key: solid black columns - before the introduction of inhaled sodium cromoglicate. First eight weeks after the introduction of inhaled sodium cromoglicate; solid white columns - weeks 1 and 2; columns with horizontal lines - weeks 3 and 4; columns with vertical lines - weeks 5 and 6; columns with diagonal lines - weeks 7 and 8.

Article Snippet: In this case we report how in a mastocytosis patient being treated with H 1 and H 2 antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement.

Techniques:

Journal: Journal of Medical Case Reports

Article Title: Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report

doi: 10.1186/1752-1947-4-193

Figure Lengend Snippet: Mean symptoms scores . Mean symptom scores covering a four week period commencing ten weeks after starting inhaled sodium cromoglicate treatment. Dosage of inhaled sodium cromoglicate 80 mg/day throughout. Menstrual bleed occurred during Week 3 of this four-week period. N.B. 'y' axis shows 0-3 range of 0-4 scale. Key: solid black columns - Week 1; columns with vertical lines - week 2; columns with horizontal lines - week 3; columns with diagonal lines - week 4.

Article Snippet: In this case we report how in a mastocytosis patient being treated with H 1 and H 2 antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement.

Techniques:

Journal: Journal of Medical Case Reports

Article Title: Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report

doi: 10.1186/1752-1947-4-193

Figure Lengend Snippet: Mean symptom scores . Mean symptom scores covering a three-week period commencing 20 weeks after starting inhaled sodium cromoglicate treatment. Menstrual bleed occurred during week 2 of this 3-week period. Dosage of inhaled SCG: 80 mg/day during week 1, 160 mg/day during week 2, 80 mg/day during week 3. N.B. 'y' axis shows 0-2 range of 0-4 scale. Key: columns with horizontal lines - week 1; columns with vertical lines - week 2; columns with diagonal lines - week 3.

Article Snippet: In this case we report how in a mastocytosis patient being treated with H 1 and H 2 antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement.

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 1 Mortality or chronic lung disease (CLD) at 28/30 days.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 2 Mortality to 28 days.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 3 CLD at 28 days.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 4 CLD at 36 weeks' postmenstrual age.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 5 CLD among survivors to 28 days.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 6 CLD among survivors to 36 weeks' postmenstrual age.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 7 Intraventricular haemorrhage.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 8 Necrotising enterocolitis.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 10 Air leak (pulmonary interstitial emphysema, pneumothorax).

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 11 Days on mechanical ventilation.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 12 Sepsis.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 9 Patent ductus arteriosus.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Cromolyn sodium versus placebo

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques:

Journal: iScience

Article Title: Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth

doi: 10.1016/j.isci.2021.103012

Figure Lengend Snippet: Increase in stroma associated mast cells promotes tumor growth following VNMAA treatment (A) Histological staining for collagen deposition (Picro-Sirius Red), mast cells (toluidine blue), and their co-localization (overlay) in a representative image of a tumor from a VNMAA-treated animal. Arrows point to mast cells. Scale bar represents 100 μm. (B) Bar and whisker plot of mast cell density (mast cells/mm 2 ) in PyMT-BO1 tumors from control and VNMAA-treated animals (left) and toluidine blue-stained MCs present in peripheral tumor stroma (dotted line denotes tumor margin; arrows point to mast cells; scale bar reprsents 50 μm. N = 2; n ≥ 13 animals per condition). (C) Mast cell counts in F. rodentium study. (D) Bar and whisker plot of mast cell density in EO771 tumors from control and VNMAA-treated animals (N = 2; n ≥ 7 animals per condition). (E) Bar and whisker plot of mast cell density in PyMT-BO1 tumors from control and cephalexin-treated animals (N = 1; n ≥ 5 animals per condition). (F) Bar and whisker plot of mast cell density in BRPKp110 tumors from control and VNMGA-treated animals (N = 1; n = 5 animals per condition). (G) Bar and whisker plot of mast cell density in d16HER2 tumors from control and vancomycin-treated animals (N = 1; n = 4 animals per condition). (H) Schematic of experimental timeline for mast cell inhibition experiment using cromolyn administered over the last 5 days of the experiment. (I) Bar plot of mean (±s.e.m.) endpoint tumor volumes of cromolyn-treated animals with either water or VNMAA versus control counterparts (N = 2); images below are photographs of representative whole tumors from each condition. Scale bar represents 5mm.

Article Snippet: From 10 days post tumor induction, animals received a daily intraperitoneal injection of cromolyn sodium (Merck Life Science) (10 mg/kg, 100 μL) alongside continued oral antibioitcs until experimental cessation 15 days after tumor induction.

Techniques: Staining, Whisker Assay, Inhibition

Journal: iScience

Article Title: Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth

doi: 10.1016/j.isci.2021.103012

Figure Lengend Snippet:

Article Snippet: From 10 days post tumor induction, animals received a daily intraperitoneal injection of cromolyn sodium (Merck Life Science) (10 mg/kg, 100 μL) alongside continued oral antibioitcs until experimental cessation 15 days after tumor induction.

Techniques: Recombinant, Staining, Modification, Transgenic Assay, Software